These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19574198)

  • 1. Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question.
    Kast RE
    Clin Transl Oncol; 2009 Jul; 11(7):408-10. PubMed ID: 19574198
    [No Abstract]   [Full Text] [Related]  

  • 2. Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug.
    Kast RE
    J Clin Pharm Ther; 2010 Dec; 35(6):657-63. PubMed ID: 21054456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.
    Kast RE; Ramiro S; Lladó S; Toro S; Coveñas R; Muñoz M
    J Neurooncol; 2016 Feb; 126(3):425-31. PubMed ID: 26603162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aprepitant--a novel NK1-receptor antagonist.
    Patel L; Lindley C
    Expert Opin Pharmacother; 2003 Dec; 4(12):2279-96. PubMed ID: 14640927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails.
    Hu W; Fang J; Nie J; Dai L; Chen X; Zhang J; Ma X; Tian G; Han J
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1129-36. PubMed ID: 24748417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study].
    Galy G; Labidi SI; Tissier F; Combes JD; Auger A; Favier B; Latour JF
    Bull Cancer; 2009 Feb; 96(2):141-5. PubMed ID: 19258220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.
    Pendergrass K; Hargreaves R; Petty KJ; Carides AD; Evans JK; Horgan KJ
    Drugs Today (Barc); 2004 Oct; 40(10):853-63. PubMed ID: 15605119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.
    Paul B; Trovato JA; Thompson J; Badros AZ; Goloubeva O
    J Oncol Pharm Pract; 2010 Mar; 16(1):45-51. PubMed ID: 19525301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aprepitant against pruritus in patients with solid tumours.
    Vincenzi B; Fratto ME; Santini D; Tonini G
    Support Care Cancer; 2010 Sep; 18(9):1229-30. PubMed ID: 20544226
    [No Abstract]   [Full Text] [Related]  

  • 10. Study flaw in comparisons of aprepitant and ondansetron.
    Cavaretta M; Noviasky J
    Am J Health Syst Pharm; 2007 Feb; 64(4):350. PubMed ID: 17299172
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
    Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
    J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis.
    Burns D; Kula J; Marshall S; Ashworth E; Ornelas M
    Adv Ther; 2020 Jul; 37(7):3265-3277. PubMed ID: 32447650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aprepitant in the prevention of vomiting induced by moderately and highly emetogenic chemotherapy.
    Wang SY; Yang ZJ; Zhang Z; Zhang H
    Asian Pac J Cancer Prev; 2014; 15(23):10045-51. PubMed ID: 25556423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
    Moore S; Tumeh J; Wojtanowski S; Flowers C
    Value Health; 2007; 10(1):23-31. PubMed ID: 17261113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
    Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aprepitant: a review of its use in the prevention of nausea and vomiting.
    Curran MP; Robinson DM
    Drugs; 2009; 69(13):1853-78. PubMed ID: 19719336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.
    Martin AR; Carides AD; Pearson JD; Horgan K; Elmer M; Schmidt C; Cai B; Chawla SP; Grunberg SM
    Eur J Cancer; 2003 Jul; 39(10):1395-401. PubMed ID: 12826042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroparesis-associated refractory nausea treated with aprepitant.
    Fahler J; Wall GC; Leman BI
    Ann Pharmacother; 2012 Dec; 46(12):e38. PubMed ID: 23191934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting.
    Van Belle SJ; Cocquyt V
    Expert Opin Pharmacother; 2008 Dec; 9(18):3261-70. PubMed ID: 19040346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.
    Warr DG; Street JC; Carides AD
    Support Care Cancer; 2011 Jun; 19(6):807-13. PubMed ID: 20461438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.